Vaccination in children receiving immunosuppressive therapy, immunosuppression
Immunosuppressive therapy in children under the attenuated, live virus vaccines, inactivated vaccines, but it certainly should not be done, in some cases, be advised. But for that month, the vaccine proved effective and is safe.
Microbial or viral diseases, frequent recurrence in cases of leukemia and severe, along with a variety of antibodies lacking the disruption or weakening of the immune mechanism is considered to be connected. As well as the Heath, a variety of bacterial infections in cases of leukemia have pointed out that after the antibody fitresinin low. Under immunosuppressive treatment of patients with leukemia or those after primary immunization or booster administration of antibodies able to synthesize the current knowledge about the capabilities, is very low.
In children with acute lymphoblastic leukemia and one case of normal children, the other immunosuppressive therapy (mercaptopurine, methotrexate, vincristine, corticosteroids), who make a study of children in the control group 2, primary inactivated vaccine or booster poliomiyelit IgG after the implementation of , studied the formation of IgA and IgM antibodies and IgG antibodies in the first group formed after the primary vaccination, but have seen this immune response is weaker than the normal control group.
Following primary vaccination with live vaccine implementation, despite the large number of booster injections, the effect of inactivated vaccine has created a poliomiyelit.
Diphtheria and tetanus immunization initiatives, the controls have resulted in lower antibody.
Children with leukemia, using inactivated measles vaccine,Strain to be instilled, and the low antibody response, immunosuppressive therapy, has announced.
Committee on Infectious Diseases (Committee on Infectious Diseases) in children with leukemia, chemotherapy, vaccination at least 3 months before the launching until after the end of the condition, and 3-12 months be vaccinated against measles.
In all these, most focused on the subject, in cases of terminal illness or leukemia patients treated with immunosuppressive result of influenza.
Influenza vaccination of children with leukemia and then found no significant difference between healthy children; ALLISON and his friends, under immunosuppressive therapy or cancer more vulnerable to influenza vaccine in children with leukemia reported a serological response has been obtained.
2-15 age group, leukemia, lymphoma or solid tumor in children with cases of influenza vaccine, administered as two doses 4 weeks apart after the seroconversion rates ranging from 75-85% face, after single dose administration of influenza vaccine, 13-60%, this ratio reported that among the changes.
These results suggest that the rate of seroconversion after two doses of influenza vaccine, as reported 37% better than the results generated by GROSS.
The differences between the results of these studies, probably between the time elapsed since vaccination history of the disease and depend on the duration of immunosuppressive therapy.
The study of pneumococcal vaccines will be discussed below.